Table of Contents
Introduction
Obesity and type 2 diabetes are two of the most common health problems in the world today. They often occur together and can lead to serious health issues, such as heart disease, kidney damage, and nerve problems. Millions of people are affected, and the numbers keep rising each year. These conditions are hard to manage, and for many people, lifestyle changes like diet and exercise are not enough. Because of this, there is a growing need for better medicines that can help lower blood sugar and support weight loss at the same time.
Over the past decade, researchers have focused on a group of medicines called GLP-1 receptor agonists. These drugs work by copying the action of a natural hormone called glucagon-like peptide-1 (GLP-1). GLP-1 helps the body release insulin when blood sugar levels are high. It also slows down digestion and reduces appetite. These effects help lower blood sugar and support weight loss. One of the most well-known medicines in this group is Semaglutide. It has been approved for both type 2 diabetes and obesity. It is available as a once-weekly injection and as a daily oral tablet.
Semaglutide has shown strong results in many large studies. People using it often lose a significant amount of weight and improve their blood sugar levels. It is used by people with type 2 diabetes, as well as those who are overweight or obese without diabetes. Because of its success, Semaglutide has become one of the leading treatments in this area. However, researchers are still trying to find even better options. This is where a new medicine called Amycretin comes in.
Amycretin is a newer drug still being studied. It is not yet approved for use, but early results look promising. Unlike Semaglutide, which targets only the GLP-1 receptor, Amycretin is a dual receptor agonist. It targets both the GLP-1 receptor and the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide. This hormone also helps with insulin release and may improve the way the body uses fat. By acting on both GLP-1 and GIP receptors, Amycretin may offer stronger effects on weight loss and blood sugar control than drugs that target only one.
Semaglutide has already made a big difference for many people, but Amycretin might take this even further. The idea of combining the action of two hormones in one medicine is exciting for both researchers and doctors. If Amycretin continues to show good results, it may become the next step in treating obesity and type 2 diabetes. Some experts believe that dual-action drugs could provide more benefits with fewer side effects, but more research is still needed to know for sure.
Another area of interest is how these medicines are taken. Many people prefer pills over injections. Semaglutide was one of the first drugs of its kind to be available in an oral form. This made it easier for more people to start treatment. Amycretin is also being tested in an oral form, which could be an advantage if it becomes approved. Having both drugs available as pills would give patients more choices and may help more people stick to their treatment plans.
The goal of new medicines like Semaglutide and Amycretin is to treat the root causes of obesity and type 2 diabetes, not just the symptoms. They work on the body’s natural hormones to help control appetite, improve insulin use, and support long-term weight loss. These effects can reduce the risk of complications and improve quality of life.
With the rise in obesity and type 2 diabetes, the need for better treatments has never been more urgent. Comparing new options like Amycretin to established ones like Semaglutide can help doctors, researchers, and patients understand which medicines work best. As more studies are done and more data become available, clearer answers will help guide decisions about treatment and care.
What Are Amycretin and Semaglutide?
Amycretin and Semaglutide are two medications being studied or used to treat obesity and type 2 diabetes. They belong to a group of drugs called incretin-based therapies, which work by mimicking natural hormones that help the body control blood sugar and appetite.
Semaglutide is already approved for use in many countries. It is part of a class called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, a hormone that helps the pancreas release insulin when blood sugar is high. It also slows down digestion and makes people feel full, which helps with weight loss.
Amycretin is a newer medication that is still being studied. It is different because it is a dual agonist. This means it activates two hormone receptors instead of one: GLP-1 and GIP. GIP stands for glucose-dependent insulinotropic polypeptide, another hormone that also helps the body manage blood sugar. By targeting both GLP-1 and GIP receptors, Amycretin may improve blood sugar and help with weight loss in a different or stronger way than GLP-1 drugs alone.
What Type of Drugs Are These?
Both Amycretin and Semaglutide are designed to act like hormones already found in the human body. These hormones are called incretins. In people without diabetes, incretins are released from the gut after eating. They help the body release insulin, control appetite, and lower blood sugar. In people with type 2 diabetes, the incretin effect is often reduced. That means the body does not release enough insulin after eating. These medications are made to help fix that problem.
Semaglutide copies the actions of GLP-1. Amycretin copies the actions of both GLP-1 and GIP. Because of this, they both fall into the category of incretin mimetics, which are used to support the natural hormone system.
How Are They Taken?
Semaglutide comes in two forms: an injection and a pill. The injection is usually taken once a week. The pill is taken once a day on an empty stomach, at least 30 minutes before food or drink. It contains an ingredient that helps the body absorb the medicine through the stomach wall.
Amycretin is being developed in an oral form, meaning it is taken by mouth as a pill. So far, it is only available through clinical trials and is not yet sold in pharmacies. Early studies are testing how well the pill works and how safe it is.
Who Makes These Medications?
Both medications are developed by Novo Nordisk, a Danish pharmaceutical company. Novo Nordisk is one of the world’s largest producers of diabetes and obesity treatments. It developed Semaglutide first, which became one of the most widely used GLP-1 medications under the brand names Ozempic (for diabetes), Wegovy (for obesity), and Rybelsus (oral form for diabetes). Amycretin is one of its newest drug candidates and is still being studied in clinical trials.
What Makes Amycretin Different from Semaglutide?
The main difference is in how the drugs work on the body. Semaglutide only activates the GLP-1 receptor. Amycretin activates both GLP-1 and GIP receptors. GIP has some different effects from GLP-1. It may help the body use fat for energy, improve insulin action in fat and muscle cells, and reduce appetite in a different way than GLP-1.
Researchers hope that by combining the effects of both hormones, Amycretin may lead to more weight loss and better blood sugar control than GLP-1 drugs alone. This is still being studied.
Another difference is that Amycretin is being developed only in a pill form. While Semaglutide also has a pill version, its injectable form is more widely used at this time. Oral Amycretin could make it easier for people to take the drug without needing an injection.
Semaglutide is a GLP-1 receptor agonist that is already approved and used for weight loss and diabetes. Amycretin is a new dual GLP-1 and GIP receptor agonist still in development. Both drugs are based on gut hormones that help control hunger, insulin, and blood sugar. Amycretin may have added effects by activating two hormone systems at once. While Semaglutide has proven benefits, Amycretin is still being studied to see if it offers more powerful results or fewer side effects.
Mechanisms of Action
Amycretin and Semaglutide are both medications used to help with weight loss and to manage type 2 diabetes. They belong to a group of medicines known as incretin-based therapies. These drugs work by copying the actions of certain natural hormones in the body that help control blood sugar and appetite. Although both drugs affect similar systems in the body, they work in different ways and may lead to different results in patients.
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist. This means it acts like a hormone called glucagon-like peptide-1 (GLP-1). GLP-1 is made in the gut after eating. It helps lower blood sugar by making the pancreas release more insulin, but only when blood sugar levels are high. Insulin is a hormone that helps move sugar from the blood into the cells, where it is used for energy.
Semaglutide also slows down how fast food leaves the stomach. This is known as delayed gastric emptying. Because of this, people feel full longer after eating, which can lead to less food intake and weight loss over time.
Another effect of Semaglutide is that it lowers the release of glucagon, a hormone that raises blood sugar. This helps reduce blood sugar levels even more, especially after meals.
In the brain, Semaglutide also helps reduce hunger signals. This leads to less appetite and fewer cravings, especially for high-calorie foods. These effects combine to help patients lose weight and manage their blood sugar levels more effectively.
How Amycretin Works
Amycretin is a dual agonist, meaning it acts on two types of hormone receptors instead of just one. Amycretin activates both GLP-1 receptors and GIP receptors. GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, GIP is another hormone made in the gut that helps control blood sugar.
By targeting both GLP-1 and GIP, Amycretin may give stronger effects than GLP-1 alone. GIP helps the pancreas release more insulin and may also help lower glucagon levels. However, its effects depend on the levels of blood sugar. When used together, GLP-1 and GIP actions may work together to improve blood sugar control more efficiently.
In addition, GIP may also help reduce appetite and increase energy use in the body. Some studies suggest that adding GIP action can improve how the body burns fat, especially when combined with GLP-1 action. This dual effect may help people lose more weight than with GLP-1 drugs alone, although more research is still ongoing.
Amycretin also slows down stomach emptying and affects hunger signals in the brain, similar to Semaglutide. But the addition of GIP action may offer extra support in fat metabolism, insulin sensitivity, and possibly in how fat is stored in the body.
Comparing the Two Mechanisms
Semaglutide works by using only the GLP-1 pathway. This has proven to be very effective for weight loss and lowering blood sugar. It improves insulin release, reduces glucagon, delays stomach emptying, and reduces hunger. These effects are well studied and used in both injection and oral forms.
Amycretin adds another layer by using the GIP pathway along with GLP-1. The idea is that dual hormone action may give better results than GLP-1 alone. By using two gut hormones, Amycretin may improve insulin secretion, appetite control, and fat burning more effectively.
It is also believed that the combination may reduce some of the side effects seen with GLP-1 agonists alone, such as nausea, but this is still being studied. Early research in animals and small human trials suggests that the GIP and GLP-1 combination can lead to greater weight loss and better blood sugar control, but larger studies are needed to confirm this.
Scientific Interest in Dual Agonists
The success of GLP-1 drugs like Semaglutide has led scientists to explore ways to make these treatments even better. Dual agonists like Amycretin are one example. Researchers believe that combining hormone actions may give stronger and more lasting results. Some even call these drugs “twin incretin” therapies.
Amycretin is not the first dual agonist in development. Another similar drug, Tirzepatide, also uses GLP-1 and GIP receptor actions and has shown strong results. Amycretin follows this same scientific idea but uses a different structure and delivery method. It is designed for oral use, which may make it more convenient for patients.
Understanding how these drugs work helps explain why some people may respond better to one than the other. It also gives doctors more tools to match the right medicine to the right patient.
Semaglutide and Amycretin both help manage obesity and type 2 diabetes by affecting hormones in the gut that control insulin, blood sugar, and appetite. Semaglutide uses the GLP-1 pathway, while Amycretin uses both GLP-1 and GIP pathways. The dual action in Amycretin may offer more powerful results, but more studies are still being done to confirm how it compares directly to Semaglutide.
Clinical Trial Results: Weight Loss Outcomes
Weight loss is one of the most important benefits of medications used to treat obesity and type 2 diabetes. Both Amycretin and Semaglutide have shown strong results in helping people lose weight. However, they work in different ways and are at different stages of research.
Semaglutide and Weight Loss: What Studies Show
Semaglutide is a GLP-1 receptor agonist. It has been widely studied and approved in many countries for weight loss and diabetes. One of the most important sets of studies is called the STEP trials. These trials looked at how well Semaglutide helped people lose weight. They included thousands of adults with obesity or who were overweight, with or without type 2 diabetes.
In the STEP 1 trial, people who took 2.4 mg of Semaglutide once a week lost about 15% of their body weight after 68 weeks. This was much more than those who received a placebo (a dummy drug), who lost only about 2.4%. This difference shows that Semaglutide works better than just lifestyle changes alone.
In STEP 2, which focused on people with type 2 diabetes, the weight loss was a bit less but still significant. People lost around 9.6% of their body weight with Semaglutide compared to 3.4% with placebo. These results show that while diabetes can make weight loss more difficult, Semaglutide is still effective.
Other studies, like SUSTAIN, looked at injectable versions of Semaglutide in people with type 2 diabetes. Though the main goal was to control blood sugar, these studies also showed good weight loss results—generally around 4% to 6% of body weight depending on the dose and length of treatment.
In general, higher doses of Semaglutide lead to more weight loss. Oral versions of Semaglutide are also available, but they are often used in lower doses and may not cause as much weight loss as the injectable form.
Amycretin and Weight Loss: Early Results
Amycretin is still in the research phase, but early trial results have shown very strong weight loss effects. Amycretin works differently from Semaglutide. It activates both GLP-1 and GIP receptors. This dual action may give it more power to reduce appetite and increase energy use.
In a small clinical trial conducted by Novo Nordisk, people with obesity took oral Amycretin daily for 12 weeks. On average, they lost about 13.1% of their body weight. This is a large amount of weight loss for such a short period. For comparison, similar weight loss with Semaglutide usually takes about a year.
The people in the trial did not have type 2 diabetes, and the study focused only on weight loss. No final data is yet available for people with diabetes or from longer trials. However, the early findings suggest that Amycretin might help people lose weight faster than current drugs, at least in the short term.
The same trial also showed that most people were able to tolerate the medication well, which is important when considering long-term use.
Comparing Amycretin and Semaglutide for Weight Loss
So far, no large head-to-head study has directly compared Amycretin and Semaglutide. But looking at early data, both drugs seem very effective for weight loss. Semaglutide has the advantage of being approved and used in many patients, so its long-term effects are better known.
Amycretin, on the other hand, is newer and still being tested. It may offer faster or greater weight loss because it affects two hormones instead of one. But more studies are needed to confirm this.
One big difference is the timing of results. Semaglutide usually shows full weight loss effects over a year. Amycretin showed strong results in just 3 months, though in a small group. It is not yet clear if that pace continues or levels off over time.
Both Amycretin and Semaglutide show strong promise for helping people lose weight. Semaglutide has already proven its value in large studies over longer periods. Amycretin’s early results are exciting, especially the speed and amount of weight loss. But it is still in testing, and more research is needed to understand its long-term effects.
For people with obesity or type 2 diabetes, these medications could become important tools in managing weight and improving health. Doctors will likely choose between them based on a person’s health history, response to treatment, and future study results.
Clinical Trial Results: Glycemic Control
Both Amycretin and Semaglutide are designed to help lower blood sugar in people with type 2 diabetes. They do this by acting on hormone systems in the body that control insulin and glucose. While Semaglutide has been studied in many large trials over several years, Amycretin is newer and has been tested in early-stage studies. Even though they are different medicines, both have shown good results in helping people reach healthier blood sugar levels.
Hemoglobin A1c Reduction
One of the most important ways to measure long-term blood sugar control is by looking at hemoglobin A1c (HbA1c). This test shows the average blood sugar level over the past 2 to 3 months. A normal HbA1c is below 5.7%, and for most people with diabetes, the goal is to stay below 7%.
Semaglutide has shown strong results in reducing HbA1c. In the SUSTAIN and PIONEER trial programs, people with type 2 diabetes who took Semaglutide had average A1c drops of 1.0% to 1.8%, depending on the dose and whether the drug was taken by mouth or injection. Many people were able to reach the target A1c level under 7%. Some even returned to near-normal blood sugar levels without using insulin.
Amycretin has also shown a strong effect on blood sugar. In an early clinical study by Novo Nordisk, people taking oral Amycretin had an A1c reduction of about 1.5% to 2.2% over 12 weeks. These results were impressive, especially since the study included people who had high blood sugar levels before starting the medicine. This suggests that Amycretin may be just as effective—or possibly even more effective—than Semaglutide in lowering A1c, although more studies are needed to confirm this.
Fasting Blood Glucose Improvements
Another key measure is fasting blood glucose (FBG), which shows how high blood sugar is after a person has not eaten for at least 8 hours. High fasting glucose levels are common in type 2 diabetes and can increase the risk of problems like heart disease and nerve damage.
Semaglutide has consistently shown that it can lower fasting blood glucose by 25 to 50 mg/dL. People often see improvements within the first few weeks of starting the medicine. These changes help the pancreas release insulin more easily and reduce how much glucose the liver makes during the night.
Amycretin also lowers fasting blood glucose. In trials, people had an average drop of 40 to 60 mg/dL, which may be slightly more than what is seen with Semaglutide. Researchers believe this may be because Amycretin activates two hormone receptors—GLP-1 and GIP—at the same time. This dual action may lead to better insulin release and better control over glucose production in the liver.
Insulin Sensitivity and Beta Cell Function
Both medicines also help improve how well the body responds to insulin. This is known as insulin sensitivity. In people with type 2 diabetes, the body’s cells often stop responding to insulin properly, which leads to high blood sugar.
Semaglutide improves insulin sensitivity by reducing inflammation and body fat, especially around the liver and belly. It also helps protect the beta cells in the pancreas, which are responsible for making insulin.
Amycretin seems to offer similar benefits. Early research shows that the GIP part of the drug may help beta cells work better over time. Some studies suggest that GIP may help beta cells grow or live longer, though this has mostly been seen in lab and animal studies so far. If this holds true in humans, Amycretin might provide longer-lasting control of diabetes by protecting the pancreas more effectively.
Time to Glycemic Target
Another way to measure success is how quickly a person reaches their target blood sugar level after starting treatment. For Semaglutide, many patients reach their A1c goal within 12 to 16 weeks. Faster responses are usually seen in people who have less severe diabetes or who are also making changes to their diet and exercise.
Amycretin has shown even faster results in some studies, with many people seeing large drops in blood sugar within just 4 to 8 weeks. This may be due to the stronger effect of dual hormone action. However, these are early results, and larger studies will be needed to confirm this advantage.
Results in Diabetic and Non-Diabetic Populations
Semaglutide has been tested in both people with type 2 diabetes and those who are overweight but do not have diabetes. In both groups, the drug helps lower blood sugar and leads to weight loss. However, the effects on blood sugar are much stronger in people who already have high glucose levels.
Amycretin has also been tested in both groups. In non-diabetics, it does not lower blood sugar below normal, which means it is unlikely to cause hypoglycemia (low blood sugar). In diabetics, it brings down blood sugar quickly and effectively. This makes it a promising option for a wide range of people, although it is not yet approved for use.
Both Amycretin and Semaglutide show strong ability to lower blood sugar and improve insulin function in people with type 2 diabetes. Semaglutide has years of data from large studies, while Amycretin is newer but has shown early signs of being even more powerful. Amycretin’s dual action may give it an edge, but more long-term research is needed to fully understand its effects. Both treatments offer promising options for managing blood sugar and improving health in people with type 2 diabetes.
Safety and Side Effects
When choosing a medication for obesity or type 2 diabetes, safety is just as important as how well the drug works. Both Semaglutide and Amycretin affect hormones that help control appetite and blood sugar. These hormones work throughout the body, which means the drugs can also cause side effects. Understanding the safety profiles of these medications helps doctors and patients make informed decisions.
Common Side Effects
Semaglutide is a well-studied drug. It is already approved in many countries for both obesity and type 2 diabetes. Most side effects reported from Semaglutide are related to the digestive system. The most common ones include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Stomach pain
These symptoms usually begin when treatment starts or when the dose is increased. For most people, they become less severe over time. Some people, however, stop taking Semaglutide because the side effects do not improve or are too uncomfortable.
Amycretin is a newer drug that is still being tested. It is a combination of two hormone-based treatments: one that targets GLP-1 receptors and one that targets GIP receptors. Early trial results suggest that Amycretin causes many of the same digestive side effects as Semaglutide. People taking Amycretin also report nausea, vomiting, and diarrhea. However, the early results suggest that these symptoms may be milder than those seen with Semaglutide. Since Amycretin is still being studied, more data are needed to know exactly how often these side effects happen and how severe they are.
Tolerability and Discontinuation Rates
Tolerability refers to how well people can handle a medication without stopping it. Some patients who use Semaglutide have to stop the drug because of side effects. In clinical trials, around 5% to 10% of patients stopped taking Semaglutide due to nausea or vomiting. This is more common when the drug is started at a high dose or increased too quickly.
The tolerability of Amycretin is still being researched. Early studies suggest that it may be better tolerated, meaning fewer people stop using it. This could be because the drug’s effect on GIP receptors may reduce nausea. However, since the trials are still small, more evidence is needed to confirm this finding.
Rare But Serious Risks
Semaglutide has been studied in thousands of patients. Because of this, researchers have been able to look for rare but serious side effects. One such concern is pancreatitis, or inflammation of the pancreas. This has been seen in some people taking GLP-1 receptor agonists like Semaglutide. It is not common, but patients with a history of pancreatitis are often told to avoid these drugs.
Another concern comes from studies in animals. In rodents, Semaglutide has been linked to thyroid C-cell tumors. These tumors have not been seen in human studies, but the warning still appears in the prescribing information. Because of this, people with a personal or family history of a rare thyroid cancer called medullary thyroid carcinoma are usually not given Semaglutide.
Amycretin has not yet been linked to pancreatitis or thyroid tumors in humans or animals. However, it is still in clinical trials, and long-term safety data are not available. As more people take the drug in studies, researchers will learn more about possible rare side effects.
Side Effects in Different Populations
The risk of side effects may also depend on who is taking the drug. For example, older adults may have more trouble with nausea or may lose too much weight. People with kidney or liver problems might also respond differently. Semaglutide has been studied in many of these groups, and its safety has been found to be similar across different populations.
For Amycretin, such detailed information is not yet available. As trials continue, researchers will look closely at how people of different ages, weights, and health conditions respond to the medication.
Semaglutide and Amycretin both affect hormones that slow digestion and reduce appetite. These effects can lead to side effects like nausea, vomiting, and diarrhea. Semaglutide is known to cause these symptoms in some people, though they often become milder over time. Amycretin appears to have a similar side effect profile, but may be slightly better tolerated. Serious risks like pancreatitis and thyroid tumors have been seen with Semaglutide but are rare. These risks have not yet been reported with Amycretin, but more studies are needed. Overall, both medications appear to be safe for most people when used properly, but doctors must watch for side effects and adjust treatment as needed.
Dosing Regimens and Administration
Both Amycretin and Semaglutide are designed to help people manage obesity and type 2 diabetes. Although they work in similar ways inside the body, their dosing and how they are taken are different. Understanding these differences can help patients and doctors make the best choice based on a person’s needs and daily routine.
Dosage Forms
Semaglutide is available in two forms: an injection and a pill. The injection is given once a week using a pen-like device. This is usually done at home and does not need a healthcare provider. The pill version, called oral Semaglutide, is taken once a day by mouth. The pill offers an option for people who do not want to take injections. This has made Semaglutide more accessible and easier to use for some patients.
Amycretin, on the other hand, is still being studied and is not yet available to the public. It is being developed as a pill, taken by mouth. So far, the company testing it, Novo Nordisk, has said it could be taken once a day. Amycretin is not available as an injection. The goal is to make it simple to use by offering it only in pill form.
How Often the Medication Is Taken
Semaglutide injections are taken once every 7 days. Patients can choose a day of the week that works best for them and continue on that schedule. This makes the treatment simple to remember. Oral Semaglutide is taken once daily. It must be taken on an empty stomach in the morning with a small sip of water, usually about 4 ounces. After taking the pill, it is important to wait at least 30 minutes before eating, drinking, or taking other medicines. This is to make sure the medicine is absorbed properly.
Amycretin, as an oral medicine still in trials, is also taken once daily. There is less public information about the exact instructions for taking Amycretin, but early data suggests it will also need to be taken on an empty stomach, possibly under similar rules to oral Semaglutide. Researchers are still studying the best way to get the most benefit from Amycretin in pill form.
Titration: Starting at Lower Doses and Going Up Slowly
Semaglutide treatment usually begins with a small dose that is slowly increased over time. This process is called titration. For example, with the weekly injection, the starting dose might be 0.25 mg. This is increased step-by-step over several weeks until the full treatment dose is reached, which can be 1.0 mg or 2.4 mg, depending on whether it is used for diabetes or obesity. The goal is to reduce side effects, especially stomach problems like nausea or vomiting.
The same idea is used with oral Semaglutide. The starting dose is often 3 mg daily. This is increased to 7 mg, and then to 14 mg depending on how well a person responds and tolerates the medicine. Doctors decide the pace based on how the patient feels and how their blood sugar and weight respond.
Amycretin is still in testing, but researchers are following a similar method of starting with lower doses and slowly increasing them. This allows the body to adjust and helps reduce side effects. More detailed titration schedules for Amycretin will likely become available after further clinical trials are finished.
Absorption and Timing
Semaglutide pills use a special ingredient called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate). SNAC helps the pill pass through the stomach lining and enter the bloodstream. Because of this, it is very important to take oral Semaglutide exactly as directed—on an empty stomach with water and no food or drink for at least 30 minutes.
Amycretin also uses a unique oral delivery system, although it may be different from SNAC. While full details have not been released, it is clear that taking it correctly will also be very important. Following the timing instructions ensures that the drug gets into the body in the right way and has the best effect.
Semaglutide gives patients two choices: a once-weekly injection or a once-daily pill. Amycretin is only being developed as a pill. Both drugs require careful timing when taken by mouth. Both may need dose adjustments over time to improve results and reduce side effects. While Semaglutide has a proven dosing plan already in use, Amycretin’s exact dosing schedule will be confirmed as more research is completed.
Understanding how each drug is taken helps patients and healthcare providers decide which treatment might fit best into someone’s daily life. Proper dosing and following instructions closely can make a big difference in how well the medicines work.
Pharmacokinetics and Bioavailability
Understanding how medications work in the body is important when comparing Amycretin and Semaglutide. Pharmacokinetics explains how the body absorbs, distributes, breaks down, and removes a drug. Bioavailability describes how much of a drug actually enters the bloodstream and is available to work. Differences in these two areas affect how well the drug works, how often it must be taken, and how it should be taken.
Absorption and Delivery
Semaglutide is a GLP-1 receptor agonist that can be taken either as a weekly injection or as a daily oral tablet. The oral form of Semaglutide uses a special technology called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate). SNAC helps the tablet survive the harsh acid in the stomach and allows it to pass through the stomach wall into the bloodstream. Without SNAC, Semaglutide would not be absorbed well when taken by mouth. For best results, oral Semaglutide must be taken on an empty stomach with plain water, and no food or drink should be consumed for at least 30 minutes afterward. This is because food can lower how much of the drug is absorbed.
Amycretin is a newer drug still in clinical trials. It is being developed as an oral drug that targets both the GLP-1 and GIP receptors. GIP stands for glucose-dependent insulinotropic polypeptide. It is another hormone involved in controlling blood sugar. Amycretin is designed to work better by targeting two different hormone systems instead of one. Early research shows that Amycretin also uses an oral delivery system to help it get absorbed through the stomach or small intestine. However, the exact technology and absorption method used in Amycretin have not yet been shared in detail.
Bioavailability
Bioavailability tells how much of the drug reaches the bloodstream. For oral Semaglutide, the bioavailability is low—around 1%. This means that only a small part of the drug taken by mouth actually enters the blood. This is why the dosing for oral Semaglutide is higher than the injected form. Even though only a small amount enters the bloodstream, it is still enough to lower blood sugar and help with weight loss.
So far, the bioavailability of oral Amycretin has not been fully reported. Since Amycretin is still in early studies, scientists are still learning how much of it is absorbed and how long it stays in the body. However, early trial results suggest that Amycretin is absorbed well enough to produce strong effects on blood sugar and body weight. Researchers are working to find the best dose that gives strong results with the fewest side effects.
Half-life and Drug Levels in the Body
Half-life is the amount of time it takes for half of the drug to leave the body. A longer half-life means the drug stays in the body for a longer time and may not need to be taken as often. Semaglutide has a long half-life of about one week, which is why it can be given once a week as an injection. Even the oral form is taken only once a day. This long-lasting action helps keep blood sugar levels steady throughout the day and night.
Amycretin also seems to have a long half-life, based on early research. Studies suggest that it builds up in the body over time, allowing for consistent levels in the blood. This is important for patients with type 2 diabetes and obesity, as it helps avoid spikes and dips in blood sugar.
Stability in the Body
Semaglutide is a synthetic version of a natural hormone, but it has been modified to last longer and resist breakdown by enzymes in the body. These changes help it remain stable in the blood for several days.
Amycretin has similar changes that protect it from being broken down too quickly. It is also designed to remain stable long enough to reach its target receptors and stay active over time. This means the body can use the drug effectively even with once-daily oral doses.
Semaglutide and Amycretin both use advanced technology to work as oral treatments for type 2 diabetes and obesity. Semaglutide uses SNAC to help it pass through the stomach wall, while Amycretin’s exact absorption method is still being studied. Both drugs are designed to be long-lasting, allowing them to be taken once daily or weekly, depending on the form. While Semaglutide has been shown to have low bioavailability, it still works well. Amycretin’s absorption and action appear strong in early studies, but more data are needed. Understanding these differences helps doctors and researchers know how these drugs work and how they can help patients manage weight and blood sugar more effectively.
Who Might Benefit More from Amycretin vs Semaglutide?
Semaglutide works by copying a natural hormone called GLP-1 (glucagon-like peptide-1). GLP-1 helps the body lower blood sugar, slows how quickly food leaves the stomach, and makes people feel full. These effects help people lose weight and improve their diabetes control.
Amycretin works in a slightly different way. It copies two hormones at once: GLP-1 and another one called GIP (glucose-dependent insulinotropic polypeptide). GIP helps the body release more insulin after eating. Scientists believe that combining GLP-1 and GIP may lead to better results than using GLP-1 alone. Amycretin’s dual action may give extra help with weight loss and blood sugar control, especially for people with obesity.
People with Obesity (Without Diabetes)
Early research suggests that Amycretin might work better than Semaglutide for people with obesity who do not have diabetes. In these people, GIP seems to improve how the body handles fat and energy. When used together with GLP-1, GIP might help reduce hunger even more and help the body burn fat more efficiently.
In one early study, people taking Amycretin lost more weight than people in past studies who took Semaglutide. This suggests that Amycretin could offer stronger weight loss for some. However, these results come from different trials, not from a direct comparison. A head-to-head study is still needed to prove this for sure.
Still, for patients focused mainly on losing weight rather than controlling blood sugar, Amycretin may offer greater benefits. This may be especially true for those who struggle with appetite or emotional eating, where stronger hunger control is helpful.
People with Type 2 Diabetes
People with type 2 diabetes may also do well on Amycretin, but the choice may depend on how severe their diabetes is. Semaglutide is already proven to lower blood sugar strongly, even in people with long-standing diabetes. It is especially helpful when the body does not make enough insulin on its own.
Amycretin may be more helpful in early-stage diabetes. In these cases, the pancreas still makes insulin, so the extra action of GIP may lead to better results. GIP helps boost insulin release after meals and may also lower insulin resistance. This means the body uses insulin more effectively, which can help reduce blood sugar levels.
For people with more advanced diabetes or those already taking insulin, Semaglutide may be the better choice. It has a stronger GLP-1 effect, which may be more important when the body’s own insulin is low.
Body Composition and Insulin Resistance
Amycretin may also benefit people who have higher levels of body fat, especially belly fat, or who have a condition called insulin resistance. This is when the body does not respond well to insulin. Both GLP-1 and GIP help improve insulin sensitivity, but combining them may offer more support for people with this problem.
GIP may also help shift how the body uses fat, encouraging the body to burn fat instead of storing it. This could help reduce body weight faster and improve metabolic health over time.
Genetic and Hormonal Differences
Some people naturally respond better to GLP-1, while others may need more help from GIP. For example, a person whose body does not respond well to GLP-1 alone might benefit from a dual-acting drug like Amycretin. On the other hand, if someone has good GLP-1 activity, Semaglutide may be enough.
Experts are still studying how genetics and hormone levels affect how well these drugs work. In the future, blood tests or other tools may help doctors choose the best medicine based on each person’s biology.
Amycretin may offer greater benefits for people with obesity who do not have diabetes, or for those with early-stage diabetes and insulin resistance. Semaglutide remains a strong choice for people with type 2 diabetes, especially when blood sugar control is the main concern. As more data becomes available, doctors will better understand how to match each medicine to the person who needs it most.
Regulatory Status and Market Availability
Semaglutide and Amycretin are both drugs made to help people with obesity and type 2 diabetes. They work by affecting hormones in the body that control blood sugar and hunger. While Semaglutide is already approved and being used in many countries, Amycretin is still being studied and is not yet available for use. Understanding where these medicines are in terms of approval and availability helps doctors and patients know what options are possible now and what might be coming soon.
Semaglutide’s Current Regulatory Status
Semaglutide is a well-known drug developed by Novo Nordisk. It is approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and many other health authorities around the world. It is available in two main forms:
- Ozempic – a once-weekly injectable form used to treat type 2 diabetes.
- Wegovy – a higher-dose, once-weekly injectable form approved for weight management in people with obesity or overweight who have weight-related medical problems.
- Rybelsus – an oral tablet version approved for type 2 diabetes.
The approval of oral Semaglutide (Rybelsus) was an important step forward. Before this, GLP-1 receptor agonists were only available as injections. Many people do not like injections, so having a tablet made it easier for some patients to start and stay on treatment. Rybelsus was approved by the FDA in 2019 for adults with type 2 diabetes. It is not yet approved for weight loss, although studies are ongoing.
In most countries, Semaglutide is now a part of the treatment options for people with type 2 diabetes. It is also prescribed for weight loss under certain conditions. Semaglutide has become a popular drug because it can help with both blood sugar control and weight reduction.
Amycretin’s Development and Regulatory Progress
Amycretin is a newer drug also developed by Novo Nordisk. It is still being tested in clinical trials. As of mid-2025, it has not been approved by the FDA, EMA, or any other health agency. Because of this, doctors cannot prescribe it yet.
Amycretin works differently from Semaglutide. It targets two hormone receptors—GLP-1 and GIP—while Semaglutide targets only GLP-1. The idea behind this is that targeting both hormones might help people lose more weight and improve blood sugar control more than GLP-1 alone. Early study results have shown promising effects, with greater weight loss in some patients compared to those taking Semaglutide.
So far, trials of Amycretin have included small groups of people. These are early-phase studies meant to test safety and get an idea of how well the drug works. Larger and longer studies are needed before health agencies can decide if the drug is safe and effective enough to be approved for use.
Novo Nordisk has announced that Amycretin is in phase 2 clinical trials, with phase 3 trials expected to begin soon. Phase 3 trials include more people and help answer more detailed questions about how well the drug works, how safe it is, and how it compares to current treatments.
Expected Timelines for Amycretin
If phase 3 trials go well, Novo Nordisk could submit Amycretin for approval by late 2026 or early 2027. After submission, health agencies like the FDA will review the data. This review can take several months to over a year, depending on the strength of the evidence and whether the agency asks for more information.
That means the earliest Amycretin might be available to patients is around 2027. This timeline can change based on trial results, manufacturing progress, or regulatory delays.
Global Availability and Future Access
Once a drug is approved, the next step is making it available in different countries. This can take more time, as each country has its own rules. For Semaglutide, this process went quickly in high-income countries. However, access has been slower in low- and middle-income regions due to cost, supply issues, and local approval processes.
For Amycretin, it is too early to know how quickly it will become available after approval. If it is proven to be very effective, Novo Nordisk may push for fast global rollout, but availability will also depend on production and pricing decisions.
Semaglutide is already approved and widely used around the world in both injectable and oral forms. It has a strong track record for treating type 2 diabetes and helping with weight loss. On the other hand, Amycretin is still being tested and is not yet approved for use. Early studies show that it might be a powerful option in the future, especially for people with obesity and diabetes. If further trials confirm its safety and effectiveness, it could be available by 2027. Until then, Semaglutide remains the main choice among GLP-1-based medications for these conditions.
Cost and Access Considerations
Understanding how much a medication costs and how easily people can get it is important when comparing treatments for obesity and type 2 diabetes. Semaglutide is already on the market and available in many countries. Amycretin is still being studied and is not yet approved for public use. However, early information about cost, insurance coverage, and availability helps give a clearer picture of how each medicine may fit into treatment plans in the future.
Cost of Semaglutide
Semaglutide is sold under brand names like Ozempic (injectable for type 2 diabetes), Rybelsus (oral form for type 2 diabetes), and Wegovy (injectable for weight loss). The cost of Semaglutide depends on the country, the brand, the dosage, and whether a person has health insurance. In the United States, the average monthly retail cost of Semaglutide without insurance ranges from $900 to $1,300.
For example:
- Ozempic: About $900–$1,100 per month
- Rybelsus (oral): Around $900–$1,000 per month
- Wegovy: Often above $1,300 per month
These prices can vary if insurance plans cover part of the cost. People with insurance might pay less, depending on their plan and their country’s health system.
In some countries with government-funded healthcare, like the United Kingdom, the cost to patients is lower because the National Health Service (NHS) or other agencies cover most of the price. However, coverage is usually limited to people who meet certain medical conditions or risk levels.
Insurance Coverage for Semaglutide
Insurance coverage is a major factor that affects who can use Semaglutide. In many cases, Semaglutide for type 2 diabetes (Ozempic or Rybelsus) is covered by insurance more easily than Semaglutide for weight loss (Wegovy). This is because diabetes medications are more commonly included in health plans, while weight-loss medications may have stricter requirements or no coverage at all.
Some insurance companies ask for proof that other treatments have failed before they will approve coverage for Semaglutide. Patients may also need to show that their body mass index (BMI) is above a certain level or that they have other health risks like high blood pressure or heart disease.
Even when Semaglutide is covered, there can still be out-of-pocket costs such as deductibles or co-payments. These added costs may be a barrier for some people, especially those with limited incomes.
Future Pricing and Access for Amycretin
Amycretin is still going through clinical trials and is not yet approved by health authorities like the FDA or EMA. Because it is not yet available for public use, there is no official price. However, as a newer drug with dual action on GIP and GLP-1 receptors, it is likely to be priced in a similar or higher range than Semaglutide once approved.
If Amycretin is released as an oral medication, it could offer more convenience, which might increase demand. Oral options are often more appealing to patients who prefer not to take injections. If demand is high and supply is limited, this could push the price even higher at launch. However, competition in the GLP-1 drug market is growing, and that may help lower prices over time.
Access to Amycretin will also depend on regulatory approval, insurance decisions, and health guidelines in each country. If Amycretin shows better weight loss or diabetes control than current drugs, some health systems may prioritize its use. But cost-effectiveness studies will play a key role in whether it is added to insurance lists or government coverage programs.
The Role of Oral Formulations in Access
Oral formulations like Rybelsus and potentially oral Amycretin may help improve access in several ways:
- Ease of use: Pills are often easier for people to take regularly than injections.
- Reduced clinic visits: Injections may require in-office training or regular monitoring, while pills can be taken at home.
- Patient preference: Some people avoid injections, even if the treatment is effective. Having a pill option may improve adherence.
However, oral formulations can still be expensive and may have special instructions for taking them (such as needing an empty stomach). These requirements may still limit who can take them safely and effectively.
As more medications for obesity and type 2 diabetes enter the market, prices may become more competitive. Generic versions of older GLP-1 drugs may help reduce overall costs. At the same time, governments, insurance companies, and healthcare providers will likely evaluate which drugs provide the most benefit for the price.
While Semaglutide is currently more widely available, Amycretin may offer new treatment options in the future. The cost and ease of getting these medications will continue to play a big role in who can benefit from them. Making sure these powerful tools are affordable and accessible will be key to managing the global rise in obesity and diabetes.
Conclusion
Amycretin and Semaglutide are two medicines being studied or used to treat people who are overweight or have type 2 diabetes. Both medicines help with weight loss and blood sugar control, but they work in different ways. Semaglutide has been approved for use in many countries. It has been tested in many large clinical trials. Amycretin is still in the research stage, but early results from studies look promising. These two treatments belong to a group of medicines called GLP-1 receptor agonists, but Amycretin also activates another hormone receptor called GIP. This extra action may help the body manage weight and blood sugar in a slightly different way.
Semaglutide works by copying the effects of a natural hormone called GLP-1. This hormone helps lower blood sugar levels by increasing insulin, slowing down how fast food leaves the stomach, and helping people feel full sooner. Because of this, many people who take Semaglutide eat less and lose weight. Amycretin works on both the GLP-1 and GIP hormone systems. GIP is another natural hormone that also affects insulin release and how the body handles energy. The idea behind using both hormone paths is to give the body a stronger signal to manage sugar and weight better than using GLP-1 alone.
When it comes to weight loss, both drugs have shown results. Clinical trials for Semaglutide, like the STEP and SUSTAIN studies, showed that people lost a large amount of weight over time. For example, some people lost around 15% of their body weight. Amycretin is still being tested in clinical trials, but early studies showed that people lost even more weight in a shorter amount of time, sometimes over 13% in just 12 weeks. However, it is important to remember that there are no direct comparison studies between these two drugs yet, so the results are based on separate trials with different conditions.
Both drugs also help control blood sugar in people with type 2 diabetes. Semaglutide has strong data showing that it can lower A1c levels and improve fasting blood sugar levels. Amycretin has shown similar effects in early trials, but more research is needed to understand how well it works in people with diabetes. So far, it seems that Amycretin may also help the body become more sensitive to insulin, which helps lower blood sugar even more.
All medicines have side effects, and both of these drugs are no exception. The most common side effects are nausea, vomiting, and stomach pain. These usually happen more at the beginning of treatment. In the trials, some people stopped taking the medicine because of these issues. Semaglutide’s side effects are well known because it has been used by many people. Amycretin’s side effects seem similar so far, but longer studies are needed to understand the risks fully. Some rare risks include inflammation of the pancreas or thyroid issues, but these have been seen mostly in animals and not confirmed in humans.
Semaglutide is available as an injection and a daily oral pill. The oral form must be taken on an empty stomach, and the body absorbs it slowly. Amycretin is being studied as an oral pill only. If approved, this may make it easier for people to take the medicine regularly. People who prefer pills over injections may find Amycretin more appealing, depending on how well it works and how it is tolerated.
Each medicine stays in the body for a long time, which is why Semaglutide can be taken once a week when injected. The pill form must be taken daily because the body absorbs it differently. Amycretin’s absorption and long-term behavior in the body are still being studied, but early reports show it may also have a lasting effect that helps with weight and sugar control over time.
Semaglutide is already approved and sold in many countries. It is used under brand names like Ozempic, Rybelsus, and Wegovy. Amycretin is still being tested and is not available for public use yet. The company that makes Amycretin, Novo Nordisk, hopes to bring it to market in the coming years, depending on how the trials go and how well the drug performs.
Cost and access also matter. Semaglutide can be expensive, especially for people who do not have insurance. Oral versions may help more people get access, but cost still plays a big role. It is not yet known how much Amycretin will cost, but if it is offered as a daily pill and is shown to work well, it could provide another useful option for many patients. Having more choices may also help bring down prices as new treatments become available.
So far, there are good reasons to be hopeful about Amycretin, but it is still early. Without head-to-head studies comparing it directly to Semaglutide, it is hard to say which one is better. More data is needed to understand how Amycretin performs in people with diabetes, how long the benefits last, and how safe it is over time.
Doctors and researchers agree that not every treatment works the same for every person. Some people may respond better to one medicine than another. Factors like age, weight, medical history, and how the body reacts to certain hormones can all play a part. For now, Semaglutide remains a proven and trusted choice. Amycretin may become an important option in the future, offering a new way to help manage weight and type 2 diabetes. The decision about which treatment to use should be based on medical needs, how well each drug works, and how well the person can tolerate it.
Research Citations
Dahl, K., Toubro, S., Dey, S., et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. The Lancet. Advance online publication. doi:10.1016/S0140-6736(25)01185-7
Gasiorek, A., Heydorn, A., Gabery, S., et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: A first-in-human, phase 1, randomised, placebo-controlled study. The Lancet. Advance online publication. doi:10.1016/S0140-6736(25)01250-4
Dahl, K., Lange, M. H., & Novo Nordisk Clinical Team. (2025, June). Amycretin, a novel unimolecular GLP-1 and amylin receptor agonist: Results of a phase 1b/2a clinical trial [Poster 2002-LB]. In 85th Scientific Sessions of the American Diabetes Association, Chicago, IL, USA.
Astbury, N. (2024, September). Safety, tolerability and weight reduction findings of oral amycretin: A novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study [Conference abstract]. European Association for the Study of Diabetes Annual Meeting, Vienna, Austria.
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity. Advance online publication. doi:10.1038/s41366-024-01473-y
Husain, M., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., & Vilsbøll, T. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 381(9), 841–851. doi:10.1056/NEJMoa1901118
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., & Haluzík, M. (2019). Efficacy and safety of oral semaglutide monotherapy versus placebo in patients with type 2 diabetes (PIONEER 1): A randomized clinical trial. Diabetes Care, 42(9), 1724–1732. doi:10.2337/dc19-0749
Pratley, R. E., Amod, A. A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M. A., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in patients with type 2 diabetes (PIONEER 4): A randomised, double-blind, phase 3a trial. The Lancet, 394(10192), 39–50. doi:10.1016/S0140-6736(19)31271-1
Pratley, R. E., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., & Araki, E. (2019). Efficacy and safety of oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin (PIONEER 2): A randomized, open-label, active-comparator trial. Diabetes Care, 42(12), 2272–2280. doi:10.2337/dc19-0883
Mosenzon, O., Blicher, T. M., Rosenlund, S., Bhattacharya, S., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Søndergaard, A. L., & Davies, M. J. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): A placebo-controlled, randomised, phase 3a trial. Lancet Diabetes & Endocrinology, 7(7), 528–539. doi:10.1016/S2213-8587(19)30192-5
Questions and Answers: Oral Amycretin vs Semaglutide
Oral amycretin is a dual agonist targeting both GLP-1 and amylin receptors, while semaglutide is a GLP-1 receptor agonist only.
Preliminary data suggest oral amycretin may result in greater weight loss than semaglutide due to its dual mechanism.
Oral amycretin is taken by mouth, while semaglutide is available in both injectable and oral forms (though the injectable version is more commonly used for weight loss).
Amycretin activates both the GLP-1 and amylin receptors, which helps suppress appetite, slow gastric emptying, and regulate blood glucose levels.
As of mid-2025, oral amycretin is still in clinical trials and has not yet received FDA approval, unlike semaglutide which is approved for type 2 diabetes and obesity.
Semaglutide has extensive long-term safety data from completed trials and real-world use, while oral amycretin is still under investigation.
Both can cause gastrointestinal side effects like nausea and vomiting. However, oral amycretin may have a distinct side effect profile due to its dual receptor activity.
Semaglutide is approved for both conditions under different brand names. Oral amycretin is being studied for similar indications but is not yet approved.
Dual agonists target multiple pathways involved in appetite and metabolism, potentially offering superior weight loss and metabolic benefits over single agonists like semaglutide.
Oral formulations generally have lower bioavailability; however, oral amycretin is being designed for effective absorption. Semaglutide’s injectable form remains more potent than its oral version.
